New Enterprise Associates, Inc., a global venture capital firm, appointed Scott Gottlieb, M.D., as a Special Partner on the firm’s healthcare investment team.
Dr. Gottlieb was a Venture Partner at NEA from 2007 to 2017 before being appointed the 23rd Commissioner of the U.S. Food and Drug Administration (FDA), where he served from 2017 to 2019.
Under Dr. Gottlieb’s leadership, the FDA advanced new policies for the safe and effective oversight of gene therapies, cell-based regenerative medicines, targeted drugs, and digital health devices; implemented new reforms to standardize drug and medical device reviews; and promoted policies to reduce death and disease from tobacco, improve food innovation and safety, advocate for better nutrition, and aggressively confront addiction crises.
In addition to his role as an investor, Dr. Gottlieb is a physician, policy expert, and advocate for healthcare entrepreneurship, innovation, and access.
He is focused on advancing public health to improve medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety.
Dr. Gottlieb is an elected member of the National Academy of Medicine and currently a Resident Fellow at the American Enterprise Institute (AEI) in Washington, DC.
In addition to his recent role as FDA Commissioner, he previously served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services.
Dr. Gottlieb was a practicing hospitalist and a Clinical Assistant Professor at the New York University School of Medicine.
Earlier in his career, he worked as a healthcare analyst for the investment bank Alex. Brown & Sons.
Dr. Gottlieb completed a residency in internal medicine at the Mount Sinai Medical Center in New York and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University in Middletown, Connecticut, where he studied Economics.